Mesoblast (NASDAQ: MESO) reported Q1 EPS of ($0.05), $0.30 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $395 thousand versus the consensus estimate of $3.69 thousand.

In line with previous guidance, the Company implemented operational streamlining measures during the quarter while achieving, and continuing to maintain progress towards, key milestones in its Tier 1 clinical programs.

For earnings history and earnings-related data on Mesoblast (MESO) click here.